Please assess the completion status of the following clinical trial:

Trial Title: Morphine Slow-release Capsules in Substitution Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Minimum age: 18 years~* Fixed abode~* At least 26 weeks of treatment (up to date) receiving a minimum dose of 50 mg methadone or~  ≥ 25 mg/day levomethadone at inclusion. Patients on levomethadone must be informed and agree to be switched to methadone~* Mature and capable of acting responsibly, in possession of all mental faculties~* Female subjects must have a negative urine pregnancy test recorded prior to the first dose of study medication and regular negative urine pregnancy tests every 4 weeks. SUB9001 - Integrated Study Protocol 10/58 June 13, 2009~* Hormonal contraception (oral, transdermal, vaginal, intrauterine or subcutaneous) by women of child-bearing age~* No intention of reducing the substitute medication during the trial~* Acceptance of the trials rules and regulations~* Acceptance to participate in the study.~Exclusion criteria:~* (Desired) pregnancy during the trial~* Breastfeeding women~* Grave or acute somatic illnesses (e.g. cardio-vascular, serious kidney or liver affection (ALAT or ASAT \> 5x augmented)) or other somatic disorder~* If suffering from severe unstable mental health problems~* If MAO-Inhibitors or are being taken~* Intracranial injury~* Intracranial hypertension~* History of epilepsy~* Severe chronic obstructive lung disease~* Chronic respiratory failure~* Known hypersensitivity to morphine or methadone~* Pancreatitis~* Paralytic ileus~* Baseline QTc interval greater than 450 msec~* Long QT Syndrome~* Patients who have participated in another clinical research study involving a new chemical entity within 3 months of study entry~* Patients with pending imprisonment at the time of inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevre-Long™ (Type: ACTIVE_COMPARATOR): slow release oral morphine
- Methadone (Type: ACTIVE_COMPARATOR): Methodone

Based on this trial design, predict the completion outcome and termination type (if applicable).